NCT06596915

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of BA1302 in Patients With Advanced Solid Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 167 (estimated)
• Sponsor: Shandong Boan Biotechnology Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).

Conditions

• Non-Small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Breast Cancer
• Melanoma

Interventions

Type	Name	Description
DRUG	BA1302	BA1302 administered intravenously

Timeline

• Start date: 2024-09-11
• Primary completion: 2025-12-31
• Completion: 2026-12-30
• First posted: 2024-09-19
• Last updated: 2025-06-06

Locations

1 site across 1 country: China